Gabrielė Poteliūnaitė

Principal

Gabrielė brings a unique perspective to venture investing, combining a scientific background in neuroscience with expertise in artificial intelligence, having earned her Master's degree in AI from Vrije Universiteit Amsterdam. She has been an active voice in the European tech ecosystem, serving as an Ambassador for Female Founders and supporting various initiatives to increase diversity in tech and venture capital.

Over the past years, she has been based and invested out of Vilnius, Tallinn, Amsterdam, Berlin and beyond.

Gabrielė joined Balnord from Heartfelt in Berlin, where she served as Principal and led investments in 20+ companies as a first check investor across Europe. Previously, she was a Senior Associate at Change Ventures, one of the leading Baltic-focused venture capital funds, where she sourced and executed investments across the Baltic ecosystem.

At Balnord, Gabrielė will focus on investments in healthcare technology, AI applications, and deep tech, aligning with the firm's thesis of backing transformative technologies.

past commitments
No items found.
Exited
Avenue Biosciences
Avenue Biosciences
2026
Seed
Finland

Avenue is commercializing a high-throughput signal peptide engineering platform that materially increases protein expression yields across biologics. This technology enables new, often previously unfeasible, therapeutic targets, for example, in cancer care, infectious diseases, and immunology, spanning antibodies, vaccines, AI-designed proteins and others.